Lumos Pharma LLC
- Address
- 2503 South Loop Drive Suite 5100
Sponsor Overview
Specializations
Growth Hormone Deficiency
Lumos Pharma LLC focuses on growth hormone deficiency in paediatric populations, with clinical activity centred on children who are naïve to treatment and those requiring ongoing monitoring for growth-related disorders.
- Prepubertal children with growth hormone deficiency
- Growth rate assessment in paediatric endocrinology
- Oral therapy for endocrine growth conditions
The sponsor’s research interest includes treatment-relevant outcomes in paediatric endocrinology, with emphasis on linear growth and clinical monitoring in children affected by insufficient growth hormone activity.
Idiopathic Growth Hormone Deficiency
Another key area of interest is idiopathic growth hormone deficiency, reflecting a focus on children whose condition is not linked to an identified underlying cause and who require specialised endocrine care.
- Idiopathic GHD in children
- Long-term safety in paediatric treatment
- Endocrine follow-up for chronic growth disorders
Clinical activity in this area centres on the management of chronic growth impairment and the evaluation of treatment tolerance over extended periods in affected children.
Paediatric Endocrinology
The sponsor’s trial portfolio is concentrated in paediatric endocrinology, with attention to disorders that affect normal development, stature, and hormonal regulation during childhood.
- Childhood hormonal growth disorders
- Hormone-related developmental care
- Monitoring of treatment safety in children
This includes clinical interest in specialist endocrine assessment, growth surveillance, and the management of children with persistent growth failure.
Oral Therapeutics for Growth Disorders
Lumos Pharma also shows interest in oral therapeutic approaches for growth disorders, particularly in settings where daily administration and sustained treatment exposure are relevant to paediatric care.
- Daily oral treatment in paediatric patients
- Safety and tolerability of endocrine therapies
- Growth-focused clinical outcomes
The company’s research activity aligns with therapeutic development for children needing ongoing support for height gain and endocrine stability.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of Oral Ibutamoren Mesylate in Prepubertal Children with Growth Hormone Deficiency: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study |  France Italy Poland Romania Spain | Not Yet Recruiting |
| Long-Term Safety Evaluation of Ibutamoren Mesilate in Pediatric Patients with Idiopathic Growth Hormone Deficiency | Poland | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 21 sites across their trial portfolio.
Therapeutic Focus
- 1.Hormonal diseases2 trials89 other sponsors
Partnered Research Centres
21 centres- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- 78 rue du Général Leclerc, 94275 Le Kremlin-Bicetre
- Address
- Via Francesco Sforza 28, 20122 Milan
- Address
- Jose Achotegui Kalea S/N, 01009 Vitoria-Gasteiz
- Address
- Passeig De La Vall D'Hebron 119-129, 08035 Barcelona
- Address
- Ul. Rzgowska 281/289, 93-338 Lodz
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Lumos Pharma LLC.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.